Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT

Inclusion Criteria: * Children (1-17) and adults (18-75 years old); * Relapsed or refractory adult and pediatric B-cell precursor ALL after HSCT; * Evidence of CD19 tumor expression in bone marrow and/or peripheral blood by flow cytometry; * Bone marrow with ≥ 5% lymphoblasts by morphologic assessment at screening; * No evidence of overall aGVHD \> Grade I or chronic GVHD (cGVHD) greater than mild at time of enrollment and in the previous 30 days; * No longer taking immunosuppressive agents for at least 30 days prior to enrollment; Exclusion Criteria: * Patients with GVHD Grades II-IV; * Any cell therapy in the last 30 days;